Publicatie

Publicatie datum

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

Kissling, E., Hooiveld, M., Sandonis Martín, V., Martínez-Baz, I., William, N., Vilcu, A.M., Mazagatos, C., Domegan, L., Lusignan, S. de, Meijer, A., Machado, A., Brytting, M., Casado, I., Murray, J.L.K., Behillil, S., Larrauri, A., O'Donnell, J., Lange, M. de, Rodrigues, A.P., Riess, M., Castilla, J., Hamilton, M., Falchi, A., Pozo, F., Dunford, L., Cogdale, J., Janssen, T., Giomar, R., Enkirch, T., Burgui, C., Sigerson, D., Blanchon, T., Martínez Ochoa, E.M., Connell, J., Ellis, J., Gageldonk-Lafeber, R. van, Kislaya, I., Rose, A.M.C., Valenciano, M. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Eurosurveillance: 2021, 26(29)

Lees online
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.